SCHOTT Pharma KGaA stock has cooled after a sharp 90 day climb of about 33%, closing today at €21.80, yet the fresh Q3 numbers tell a more resilient story. Revenue reached €281.76m and basic earnings per share came in at €0.26, supported by an earnings before interest, tax, depreciation and amortisation margin of 26.8% that still sits in the high twenties.
That mix of strong profitability and a trailing P/E of 24.1x, below both life sciences peers and the sector average, sets up a picture that differs from what the latest price wobble suggests.
Is SCHOTT Pharma KGaA trading at a genuine discount, or does the lower P/E and DCF gap mask hidden risks? Compare the current price to our fair value work in the valuation analysis for SCHOTT Pharma KGaA.Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): €281.76m vs. €256.46m (up about 10%)
- Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): €38.83m vs. €45.56m (down about 15%)
- Basic EPS (Q3 2026 vs Q3 2025): €0.26 vs. €0.30 (down about 13%)
- EBITDA Margin (Q3 2026 vs prior year Q3 margin level): 26.8% in Q3 2026, in the high twenties and slightly below the prior year level
Prefer clear charts instead of picking through another wall of earnings tables and ratios? See SCHOTT Pharma KGaA’s full financial picture, with a visual breakdown of its valuation in the company report for SCHOTT Pharma KGaA..
HVS momentum keeps SCHOTT Pharma’s bull case intact
Bulls argue SCHOTT Pharma can shift the business toward higher value solutions, lift mix and protect margins even while investing heavily. Q3 data largely backs that up. HVS reached 59% of revenue, almost at the 60% midterm ambition, and Drug Containment Solutions grew on sterile cartridges, specialty vials and ready to use formats. Group EBITDA margin of 26.8% sits close to the full year target range of 27% to 28% despite higher depreciation and ramp costs. Free cash flow for the first nine months improved 49% to €58.9m even with €82.5m of capex, which fits the thesis that new capacity in Lebanon and Europe is beginning to carry more of its own weight. The upgraded 2026 revenue and margin guidance, and confirmed outlook in July, are further milestones for the mix and profitability story.
Bear worries on mix, DDS and contract quality partially persist
The bear narrative centers on product mix risk, weaker Drug Delivery Systems and contract vulnerability eating into earnings quality. Q3 and nine month results give that concern some support. Group EBITDA margin for the first nine months is 26.7%, below the prior year level of 28.9%, and net income over the period declined 9% to €103.4m despite solid revenue progress. DDS revenue for the first nine months is slightly lower year on year and its EBITDA is down 16.3%, weighed by lower utilization, optimization costs and an earlier syringe inventory impairment. Management also disclosed that around €15m of this year’s growth comes from a one off contract element that will not repeat, which means part of the current step up will be a tougher comparison for 2027. Polymer syringe recovery is described as broad based but still lacks quantified traction.
With EBITDA margins below prior year levels, capex still elevated and part of SCHOTT Pharma KGaA’s growth tied to a non recurring contract, it is worth verifying how robust the balance sheet really is. Check the financial health analysis of SCHOTT Pharma KGaA stock.Stay Ahead With Simply Wall St
If the mix of SCHOTT Pharma KGaA’s resilient profitability, lower P/E and the fair value debate has your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch how the story develops. After you take a position, use the Portfolio Command Center to cut through market noise and focus on the updates that really matter to your holdings. For a longer term view, tap into crowd insights and different angles on SCHOTT Pharma KGaA and other stocks through the Community. This way you can spot potential catalysts and risks early and stay ahead of the market.
Seeking Alternatives Beyond SCHOTT Pharma?
Fresh ideas can move quickly once momentum hits. Scan for breakout potential while it is still under the radar. Avoid reacting late by planning ahead instead of rushing.
- Chase quality first by scanning a curated 251 high quality undervalued stocks list that combines solid balance sheets with strong cash flows before the crowd starts pricing in the potential.
- Spot real businesses behind the AI hype by checking 71 profitable AI stocks that aren't just burning cash where earnings already support the story instead of relying only on headlines and promises.
- Target staying power as conditions shift with a focused set of 293 resilient stocks with low risk scores designed to keep drawdown risk contained while you pursue upside.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com